Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Esophageal Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Esophageal Cancer (163
)
Esophageal Squamous Cell Carcinoma (73
)
Esophageal Cancer (163
)
Esophageal Squamous Cell Carcinoma (73
)
›
Associations
(32)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
RET fusion
Esophageal Adenocarcinoma
RET fusion
Esophageal Adenocarcinoma
selpercatinib
Sensitive: A2 - Guideline
NCCN - 4 weeks (New A2)
selpercatinib
Sensitive
:
A2
NCCN - 4wk
selpercatinib
Sensitive: A2 - Guideline
NCCN - 4 weeks
selpercatinib
Sensitive
:
A2
NCCN - 4 weeks - (New A2)
BRAF V600E
Esophageal Adenocarcinoma
BRAF V600E
Esophageal Adenocarcinoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
NCCN - 4 weeks (New A2)
trametinib + dabrafenib
Sensitive
:
A2
NCCN - 4wk
trametinib + dabrafenib
Sensitive: A2 - Guideline
NCCN - 4 weeks
trametinib + dabrafenib
Sensitive
:
A2
NCCN - 4 weeks - (New A2)
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
FLOT
Sensitive: A2 - Guideline
FLOT
Sensitive
:
A2
FLOT
Sensitive: A2 - Guideline
FLOT
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
PD-L1 overexpression
Esophageal Adenocarcinoma
PD-L1 overexpression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
PD-L1 underexpression
Esophageal Adenocarcinoma
PD-L1 underexpression
Esophageal Adenocarcinoma
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
Immunotherapy
Resistant: B - Late Trials
Immunotherapy
Resistant
:
B
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
trastuzumab + pertuzumab
Sensitive
:
C1
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
trastuzumab + pertuzumab
Sensitive
:
C1
MSI-H/dMMR
Esophageal Adenocarcinoma
MSI-H/dMMR
Esophageal Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
nivolumab + ipilimumab
Sensitive
:
C1
nivolumab + ipilimumab
Sensitive: C1 - Off-label
nivolumab + ipilimumab
Sensitive
:
C1
CLDN18.2 expression
Esophageal Adenocarcinoma
CLDN18.2 expression
Esophageal Adenocarcinoma
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
IMAB362
Sensitive: C2 – Inclusion Criteria
IMAB362
Sensitive
:
C2
HER-2 amplification
Esophageal Adenocarcinoma
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + avelumab
Sensitive
:
C2
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + avelumab
Sensitive
:
C2
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
paclitaxel
Resistant: C3 – Early Trials
paclitaxel
Resistant
:
C3
paclitaxel
Resistant: C3 – Early Trials
paclitaxel
Resistant
:
C3
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
carboplatin
Resistant: C3 – Early Trials
carboplatin
Resistant
:
C3
carboplatin
Resistant: C3 – Early Trials
carboplatin
Resistant
:
C3
ARID1A mutation
Esophageal Adenocarcinoma
ARID1A mutation
Esophageal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
DKK1 overexpression
Esophageal Adenocarcinoma
DKK1 overexpression
Esophageal Adenocarcinoma
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
pembrolizumab + DKN-01
Sensitive
:
C3
pembrolizumab + DKN-01
Sensitive: C3 – Early Trials
pembrolizumab + DKN-01
Sensitive
:
C3
DKK1 overexpression
Esophageal Adenocarcinoma
DKK1 overexpression
Esophageal Adenocarcinoma
DKN-01
Sensitive: C3 – Early Trials
DKN-01
Sensitive
:
C3
DKN-01
Sensitive: C3 – Early Trials
DKN-01
Sensitive
:
C3
GRB7 positive
Esophageal Adenocarcinoma
GRB7 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
HER-2 overexpression
Esophageal Adenocarcinoma
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
ERCC1 negative
Esophageal Adenocarcinoma
ERCC1 negative
Esophageal Adenocarcinoma
SOX
Sensitive: C3 – Early Trials
SOX
Sensitive
:
C3
SOX
Sensitive: C3 – Early Trials
SOX
Sensitive
:
C3
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
nivolumab + trastuzumab
Sensitive: C3 – Early Trials
nivolumab + trastuzumab
Sensitive
:
C3
nivolumab + trastuzumab
Sensitive: C3 – Early Trials
nivolumab + trastuzumab
Sensitive
:
C3
PD-L1 overexpression
Esophageal Adenocarcinoma
PD-L1 overexpression
Esophageal Adenocarcinoma
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
durvalumab
Sensitive: C3 – Early Trials
durvalumab
Sensitive
:
C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
TP53 mutation
Esophageal Adenocarcinoma
TP53 mutation
Esophageal Adenocarcinoma
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login